Clinical Trial Update: Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038) [Phase 3]

View source ↗

Summary

A Phase 3 comparative study evaluating immunogenicity and safety of a two-dose Regimen of ProQuad manufactured with rHA (V221-038) for measles and mumps (with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Measles
• Mumps
• Rubella
• Varicella

Drugs mentioned

• ProQuad (Measles, Mumps, Rubella and Varicella live attenuated vaccine)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Measles, Mumps | Phase 3 | Status: COMPLETED | Results posted: 2018-01-30